SecA

SecA
Name	SecA
Taxonomic range	Bacteria

SecA

Introduction

SecA is an essential bacterial ATPase involved in protein translocation across the cytoplasmic membrane. It works with the SecYEG translocon to move preproteins and collaborates with chaperones and ribosomes to ensure proper secretion. Research on SecA involves groups studying Antonie van Leeuwenhoek, Louis Pasteur, Max Delbrück, Howard Temin, and institutions such as the Max Planck Institute, Harvard University, University of Cambridge, and Stanford University that contributed to understanding secretion through biochemical, structural, and genetic approaches.

Structure and Mechanism

SecA is a dimeric enzyme comprising multiple domains including the DEAD-box ATPase motor and the preprotein cross-linking region; structural studies used methods from Rosalind Franklin-era crystallography to modern cryo-electron microscopy developed by teams at MRC Laboratory of Molecular Biology, EMBL, and Cold Spring Harbor Laboratory. High-resolution structures revealed nucleotide-binding pockets homologous to those in AAA+ ATPases characterized by researchers like Arthur Kornberg and Paul Boyer, and domains that undergo large conformational changes reminiscent of the mechanisms described for F1-ATPase and ClpX. SecA cycles between ATP-bound and ADP-bound states, where coordinated motions of the two-helix finger and the preprotein binding domain push polypeptide segments through the translocon, a mechanism informed by thermodynamic principles similar to those explored by Ludwig Boltzmann and Josiah Willard Gibbs.

Role in Protein Translocation

SecA drives post-translational translocation through the SecYEG channel embedded in the bacterial inner membrane, a pathway elucidated by geneticists at institutions such as University of California, Berkeley and biochemical labs associated with Max Planck Society. SecA recognizes signal peptides typically processed by signal peptidases known from work at Weizmann Institute of Science and collaborates with cytosolic chaperones analogous to those studied by Kishore Rao and groups at Rockefeller University. The motor action of SecA is coordinated with ribosomal translation in co-translational pathways investigated by research teams at European Molecular Biology Laboratory and MIT, and it interfaces with membrane protein insertion systems comparable to those studied in organellar translocation in labs at University of Oxford.

Regulation and Interactions

SecA activity is regulated by nucleotide exchange, oligomeric state, and interactions with proteins such as SecB and signal recognition particle (SRP) components, topics advanced by laboratories at Johns Hopkins University and Yale University. Post-translational modifications and proteolytic control resembling regulatory themes probed by groups at Salk Institute influence SecA stability and turnover; regulatory networks have parallels with stress responses investigated by scientists at National Institutes of Health and Centers for Disease Control and Prevention. SecA engages with the SecYEG complex, membrane phospholipids characterized by researchers at ETH Zurich, and accessory factors whose discovery involved collaborations with teams at University of Tokyo and Seoul National University.

Evolution and Homologs

SecA is conserved across many bacterial phyla, with homologs and paralogs identified through comparative genomics efforts led by consortia such as the Genome Project-Write and databases maintained by European Bioinformatics Institute and National Center for Biotechnology Information. Evolutionary analyses place SecA within a family related to DEAD/DEAH-box helicases and AAA+ proteins studied by groups at Carnegie Institution for Science and Howard Hughes Medical Institute investigators. Divergent SecA-like proteins in endosymbionts and organelles show parallels to protein translocation systems in mitochondria and chloroplasts researched at University of California, San Diego and University of Chicago.

Clinical and Biotechnological Relevance

SecA is a potential target for novel antibiotics discovered through screening programs at pharmaceutical companies like Pfizer, Novartis, and GlaxoSmithKline, and academic drug-discovery centers at Imperial College London and University of Pennsylvania. In biotechnology, engineered SecA-dependent secretion pathways enable recombinant protein production in industrial strains optimized by teams at Amgen and Genentech; improvements draw on fermentation and process engineering advances from Delft University of Technology and Massachusetts Institute of Technology. Mutations affecting SecA function have implications for pathogenicity in organisms studied by researchers at Centers for Disease Control and Prevention and Wellcome Trust Sanger Institute, motivating translational efforts at medical centers such as Mayo Clinic and Cleveland Clinic.

Category:Bacterial proteins